Lakeland PeptidesPeptide therapy, explained · Lakeland & Polk County, FL

Goal

Peptides and Healthy Aging: A Plain-Language Guide for Lakeland

Not reviewed by a licensed provider. Read our disclaimer

Last updated

“Anti-aging” is one of the most common reasons clinics give for peptide therapy. This page explains which peptides are marketed for healthy aging, what research has and has not shown, and what to ask before you start. It is general information, not advice for your situation.

Overview

Peptides sold for anti-aging fall into a few groups. Some prompt the body to release more growth hormone. Others are promoted for telomeres, mitochondria, skin or the brain. A few have FDA approval for a narrow medical use. Most do not.

The key point is simple: no peptide has been shown to slow aging, extend life or prevent age-related disease in people. Many studies measure a lab marker, such as a hormone level, rather than a health outcome. A higher hormone level is not the same as living longer or feeling better.

It also helps to know what happened when growth hormone itself was tested. A review of randomized trials in healthy older adults found that growth hormone lowered fat mass by about 2 kg and raised lean mass by about 2 kg. It also caused more swelling, joint pain, carpal tunnel syndrome and breast tissue growth in men. The reviewers concluded it cannot be recommended as an anti-aging therapy.1

Peptides used for anti-aging

Growth hormone boosters

  • Sermorelin (some human trials). A copy of part of the brain hormone that tells the pituitary to release growth hormone. It was once FDA-approved as Geref for children with one type of growth hormone deficiency. Its maker stopped selling it in 2008, for reasons FDA says were not about safety or effectiveness.2 In a 6-week study of 11 healthy older men, it raised nighttime growth hormone but did not change IGF-1, body fat or muscle.3
  • Tesamorelin (FDA-approved for one use). Approved only to reduce excess belly fat in adults with HIV-related lipodystrophy.4 In one 20-week trial of 152 older adults, it had a modest effect on thinking tests that has not been confirmed.5
  • CJC-1295 (very limited human data). A lab-made relative of the same brain hormone, classed by anti-doping rules as a growth hormone-releasing hormone analog.6 It has never been FDA-approved.7 FDA lists serious adverse events linked to it, including a fast heart rate and a body-wide widening of blood vessels, and says clinical data are limited.8
  • Ipamorelin (very limited human data). Triggers growth hormone release through the ghrelin receptor. No human trial has measured muscle, fat, sleep or aging outcomes, and FDA found no human data for the under-the-skin injections clinics use.9
  • GHRP-2 (some human trials, for diagnosis). Approved in Japan only as a one-time test for growth hormone deficiency.10 Like GHRP-6, it has no controlled trial for any anti-aging goal.11
  • GHRP-6 (very limited human data). An older ghrelin-like peptide. Along with growth hormone, it and GHRP-2 also raise the stress hormone cortisol and increase appetite.11

“Longevity” and mitochondria peptides

  • Epitalon (very limited human data). A four-amino-acid peptide developed in Russia. In its key mouse study, it did not increase average lifespan; only the longest-lived mice lived somewhat longer.12 One lab study outside the original group, later corrected, reported telomere lengthening in cells, including cancer cells by a different mechanism.13 FDA found no human safety studies.14
  • MOTS-c (animal and lab data only). A peptide made by the body’s mitochondria. In one study of old male mice, injections modestly extended lifespan. FDA found no studies giving it to people.15
  • SS-31 (elamipretide) (FDA-approved for one rare disease). Approved only for muscle strength in Barth syndrome, a rare inherited disease.16 In a 218-person trial in a more common mitochondrial muscle disease, it did not improve walking or fatigue.17

Skin and immune peptides

  • GHK-Cu (very limited human data). A copper peptide common in skin creams. In a small randomized trial after laser skin treatment, it did not improve measured redness, wrinkles or skin quality, though users rated their skin better.18 Claims that it “resets genes” come from computer analyses by researchers tied to the peptide.19 See our skin and hair page.
  • Thymosin alpha-1 (some human trials). An immune-signaling peptide from the thymus gland. Reviews report it is approved in more than 35 other countries, mainly for hepatitis B and C,20 but it is not FDA-approved.21 In a 1,106-person sepsis trial, death rates were nearly the same as with placebo.22 It has not been shown to strengthen immunity in healthy older people.

Brain (“nootropic”) peptides

  • Semax (very limited human data). Nose drops registered in Russia. FDA found “insufficient evidence” of effectiveness for the uses it reviewed, which included the “nootropic” claim.23
  • Selank (very limited human data). Nose drops sold in Russia for anxiety. Its main study, reported in Russian, compared it with another anti-anxiety drug rather than a placebo.24

What to realistically expect

  • Hormone changes are not health outcomes. Growth hormone boosters can raise growth hormone or IGF-1, a related hormone. But small studies in older adults showed little or no change in body composition, and none measured disease or lifespan.3
  • Animal results rarely translate directly. Mouse lifespan findings for epitalon and MOTS-c come from single studies, and the epitalon study did not change average lifespan.1215
  • The 2026 regulatory news is not approval. An FDA advisory committee voted in July 2026 to recommend allowing pharmacies to compound epitalon, semax and MOTS-c. FDA’s own reviewers had recommended against it, and the votes are not binding. Reported votes were 7 to 4 for epitalon and 8 to 5 for semax, each with 1 abstention.25 As of November 13, 2026, HHS has published a draft, non-binding policy saying it does not intend to take enforcement action against licensed pharmacies compounding certain peptides in certain forms. This is not FDA approval, and FDA has not added them to its official list.26 According to law-firm summaries, the draft covers epitalon, semax and MOTS-c, among others.27 As of November 13, 2026, a final policy had not been published. Check the Federal Register notice for updates.26

Healthy aging still rests mostly on sleep, activity, strength training, nutrition, not smoking, and managing conditions like blood pressure and diabetes. A peptide is not a substitute for those.

Safety considerations

  • Growth hormone effects. Tesamorelin pushed IGF-1 above the normal range in many patients and raised the risk of high blood sugar. Its label lists cancer risk as a warning.4 For ipamorelin, FDA says growth hormone risks such as tumor growth, diabetes and fluid retention cannot be ruled out.9
  • Cortisol and appetite. GHRP-2 and GHRP-6 raise cortisol and appetite as well as growth hormone.11
  • Theoretical cancer concern. FDA raised a concern that turning on telomerase, as epitalon is claimed to do, could help cells keep dividing.14
  • Unknowns. For MOTS-c, FDA says the risks in humans “are unknown.”15 SS-31’s label warns of serious allergic reactions.16
  • Compounded and “research” products. FDA lists immune reactions and impurities as concerns for many of these peptides.8 See our guide to research-chemical peptide risks.
  • Athletes. WADA’s 2026 list bans growth hormone-releasing peptides, including sermorelin, tesamorelin, CJC-1295, ipamorelin, GHRP-2 and GHRP-6, at all times.6

Questions to ask a provider

  • What specific outcome are you trying to improve, and how will we measure it?
  • What human evidence supports this peptide for that outcome?
  • Is this an FDA-approved product, a compounded product, or something else? Which pharmacy makes it?
  • What lab work will you do before and during treatment, and why?
  • How does this compare with hormone therapy that is FDA-approved for my situation? Our peptides vs. TRT/HRT guide can help.
  • What side effects should I watch for, and when would we stop?
  • What is the total cost, and what does it include?

Our guide on how to vet a peptide clinic can help you spot red flags.

Footnotes

  1. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-115. https://doi.org/10.7326/0003-4819-146-2-200701160-00005 ↩

  2. Food and Drug Administration. Determination that GEREF (sermorelin acetate) injection […] were not withdrawn from sale for reasons of safety or effectiveness. Fed Regist. 2013;78(42):14095-14096. https://www.federalregister.gov/d/2013-04827 ↩

  3. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. https://doi.org/10.1016/s0026-0495(97)90174-8 ↩ ↩2

  4. Theratechnologies. EGRIFTA WR (tesamorelin) for injection: prescribing information. Revised March 2025. FDA Reference ID 5557578. ↩ ↩2

  5. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. https://doi.org/10.1001/archneurol.2012.1970 ↩

  6. World Anti-Doping Agency. The Prohibited List 2026. In effect January 1, 2026. https://www.wada-ama.org/en/prohibited-list ↩ ↩2

  7. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting, December 4, 2024: CJC-1295-related bulk drug substances. 2024. https://www.fda.gov/media/183819/download ↩

  8. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of April 22, 2026. Accessed November 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks ↩ ↩2

  9. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, October 29, 2024: evaluation of ipamorelin-related bulk drug substances for inclusion on the 503A Bulk Drug Substances List. 2024. https://www.fda.gov/media/182088/download ↩ ↩2

  10. Kaken Pharmaceutical Co., Ltd. GHRP Kaken 100 for injection (pralmorelin hydrochloride) package insert, 3rd revision. Pharmaceuticals and Medical Devices Agency (Japan). July 2025. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/200022_7223407D2023_1_01 ↩

  11. Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol (Lausanne). 2026;17:1822475. https://doi.org/10.3389/fendo.2026.1822475 ↩ ↩2 ↩3

  12. Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. https://doi.org/10.1023/a:1025114230714 ↩ ↩2

  13. Al-Dulaimi S, Thomas R, Matta S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. https://doi.org/10.1007/s10522-025-10315-x ↩

  14. U.S. Food and Drug Administration. FDA evaluation of epitalon-related bulk drug substances (epitalon free base and epitalon acetate). Pharmacy Compounding Advisory Committee briefing document. 2026. https://www.fda.gov/media/193345/download ↩ ↩2

  15. Li J, Poon N-L, Asante K, et al. FDA evaluation of MOTS-c-related bulk drug substances. U.S. Food and Drug Administration; memo dated May 11, 2026. https://www.fda.gov/media/193347/download ↩ ↩2 ↩3

  16. Stealth BioTherapeutics. FORZINITY (elamipretide) injection: prescribing information. Revised September 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf ↩ ↩2

  17. Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238-e252. https://doi.org/10.1212/WNL.0000000000207402 ↩

  18. Miller TR, Wagner JD, Baack BR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259. https://doi.org/10.1001/archfaci.8.4.252 ↩

  19. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. https://doi.org/10.3390/ijms19071987 ↩

  20. Dominari A, Hathaway D III, Pandav K, et al. Thymosin alpha 1: a comprehensive review of the literature. World J Virol. 2020;9(5):67-78. https://doi.org/10.5501/wjv.v9.i5.67 ↩

  21. U.S. Food and Drug Administration. Drugs@FDA data via openFDA (drugsfda endpoint). Data last updated November 12, 2026. https://api.fda.gov/drug/drugsfda.json ↩

  22. Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583. https://doi.org/10.1136/bmj-2024-082583 ↩

  23. U.S. Food and Drug Administration. FDA evaluation of semax-related bulk drug substances (semax free base and semax acetate). Pharmacy Compounding Advisory Committee briefing document; memo dated May 11, 2026. https://www.fda.gov/media/193348/download ↩

  24. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia [in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. https://pubmed.ncbi.nlm.nih.gov/18454096/ ↩

  25. McDermott Will & Schulte. Bulk list bound: PCAC backs majority of peptides in two-day public meeting. July 27, 2026. https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/ ↩

  26. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (notice of availability). Fed Regist. 2026;91(209):68526-68527. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances ↩ ↩2

  27. Sklamberg H, Kumar D, Trentacost E. HHS announces draft enforcement discretion policy paving way for pharmacies. Arnold & Porter. November 2, 2026. https://www.arnoldporter.com/en/perspectives/advisories/2026/11/hhs-announces-draft-enforcement-discretion-policy-paving-way-for-pharmacies ↩

Frequently asked questions

Can peptides slow aging?

No peptide has been shown to slow aging or extend life in people. The 'longevity' claims come mostly from cell and animal studies, and in the main mouse study of epitalon, average lifespan did not change.

Are sermorelin and ipamorelin the same as growth hormone?

No. They signal the body to release more of its own growth hormone. When growth hormone itself was tested in healthy older adults, it shifted fat and lean mass a little but caused more swelling and joint pain, and reviewers said it could not be recommended for anti-aging.

Is SS-31 an FDA-approved anti-aging peptide?

No. Elamipretide (SS-31) is FDA-approved only to improve muscle strength in a rare inherited disease, Barth syndrome. A larger trial in a more common mitochondrial muscle disease found no benefit.

Do I need lab work before starting?

A careful provider will usually want a health history and lab work before prescribing peptides that affect hormones. Ask what they plan to check and why.

Questions? Talk to a licensed provider

See a free list of top rated clinics in Lakeland and Polk County, with their phone numbers and Google reviews. No one will call you.

Find a top rated provider
Find a top rated provider today